Opioid metabolism

Mayo Clinic Proceedings

Volumn 84, Issue 7, 2009, Pages 613-624

  Smith, Howard S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CODEINE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DIHYDROCODEINE; DIHYDROMORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; NALOXONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYMORPHONE; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; CYTOCHROME P450; PRODRUG;

ALLODYNIA; ANALGESIA; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENZYME SUBSTRATE; FIRST PASS EFFECT; GLUCURONIDATION; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER METABOLISM; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MYOCLONUS; NAUSEA; PATIENT COMPLIANCE; PRESCRIPTION; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING; METABOLISM; OPIATE ADDICTION; PAIN; PHYSIOLOGY;

ANALGESICS, OPIOID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PRODRUGS;

EID: 67650736252     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.7.613     Document Type: Review

References (116)

1. World Health Organization. Cancer Pain Relief: With a Guide to Opioid Availability. 2nd ed.Geneva, Switzerland: WHO Office of Publication; 1996.
2. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2004;100(6):1573-1581.
3. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50(6)(suppl): S205-S224.
4. American Pain Society. Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis. 2nd ed. Glenview, IL: American Pain Society; 2002:184.
5. Andersson GB. Epidemiological features of chronic low-back pain. Lancet. 1999;354(9178):581-585.
6. Grilo RM, Bertin P, Scotto di Fazano C, et al. Opioid rotation in the treatment of joint pain: a review of 67 cases. Joint Bone Spine. 2002;69(5):491-494.
7. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86(9):1856-1866.
8. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006 Jun;32(4):304-315. Epub 2006 Apr 19.
9. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000;90(4):933-937.
10. Duragesic (fentanyl transdermal system) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2008.
11. OxyContin (oxycodone HCl controlled-release tablets) [package insert]. Stamford, CT: Purdue Pharma LP; 2007.
12. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos. 1998;26(1):73-77.
13. Codeine Contin (codeine controlled-release tablets) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; 2006.
14. Hydrocodone [package insert]. Corona, CA: Watson Laboratories; 2004.
15. Methadone hydrochloride tablets [package insert]. Hazelwood, MO: Mallinckrodt, Inc; 2004.
16. Ultram ER (tramadol hydrochloride) [package insert]. Raritan, NJ: Ortho-McNeil; 2008.
17. Dilaudid-HP injection 10 mg (hydromorphone hydrochloride) full prescribing information. North Chicago, IL: Abbott Laboratories; 2008.
18. OPANA ER (oxymorphone hydrochloride extended-release tablets) [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2008.
19. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol. 1999;47(4):403-412.
20. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007 Apr;321(1):389-399. Epub 2007 Jan 26.
21. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003;31(6):742-747.
22. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008;12(2):109-124.
23. Crettol S, Déglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80(6):668-681.
24. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687-710.
25. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9(4):310-322.
26. Girennavar B, Jayaprakasha GK, Patil BS. Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J Food Sci. 2007;72(8):C417-C421.
27. Huber WW, Rossmanith W, Grusch M, et al. Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol. 2008;46(4):1230-1238.
28. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. http://medicine.iupui.edu/flockhart/ table.htm. Accessed March 5, 2009.
29. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17(2):102-105.
30. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1998;64(6):603-611.
31. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin [published correction appears in Clin Pharmacol Ther. 1994;55(6):648]. Clin Pharmacol Ther. 1992;51(4):388-397.
32. Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brosen K. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics. 1998;8(2):119-123.
33. Løvlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392(1):30-34.
34. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol. 1991;32(4): 504-507.
35. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996;278(1):441-446.
36. Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Hørder M, Brøsen K. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol. 1999;48(3):395-401.
37. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991;50(3):308-313.
38. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol. 1996;42(6):713-719.
39. Mbanefo C, Bababunmi EA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica. 1980;10(11):811-818.
40. Lötsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43(14):983-1013.
41. Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract. 2007 Dec;7(4):352-356. Epub 2007 Nov 6.
42. Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1356-1358. Epub 2006 Apr 24.
43. Kadian (morphine sulfate extended-release capsules) [package insert]. Piscataway, NJ: Alpharma; 2008.
44. Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics. 2000; 10(8):679-685.
45. Hara Y, Nakajima M, Miyamoto K, Yokoi T. Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. Drug Metab Pharmacokinet. 2007;22(2):103-112.
46. Projean D, Morin PE, Tu TM, Ducharme J. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica. 2003;33(8):841-854.
47. Takeda S, Ishii Y, Iwanaga M, et al. Modulation of UDP- glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol. 2005;67(3):665-672. Epub 2004 Dec 20.
48. Takeda S, Ishii Y, Mackenzie PI, et al. Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull. 2005; 28(10):2026-2027.
49. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol. 2008;83(3):200-202.
50. Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther. 2004;75(3):223-233.
51. Toide K, Takahashi Y, Yamazaki H, et al. Hepatocyte nuclear factor-1α is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers. Drug Metab Dispos. 2002;30(6):613-615.
52. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001;19(11):2898-2904.
53. Cone EJ, Caplan YH, Moser F, Robert T, Black D. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol. 2008;32(4):319-323.
54. Cone EJ, Heit HA, Caplan YH, Gourlay D. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol. 2006;30(1):1-5.
55. McDonough PC, Levine B, Vorce S, Jufer RA, Fowler D. The detection of hydromorphone in urine specimens with high morphine concentrations. J Forensic Sci. 2008;53(3):752-754.
56. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004;57(3): 287-297.
57. DrugBank Web site. Departments of Computing & Biological Sciences, University of Alberta. http://drugbank.ca. Accessed March 5, 2009.
58. Oyler JM, Cone EJ, Joseph RE Jr, Huestis MA. Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol. 2000;24(7):530-535.
59. Oda Y, Kharasch ED. Metabolism of methadone and levo-α- acetyl-methadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001;298(3):1021-1032.
60. Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007;37(4):301-314.
61. Dalén P, Frengell C, Dahl ML, Sjöqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit. 1997;19(5):543-544.
62. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism [published correction appears in N Engl J Med. 2005;352(6):638]. N Engl J Med. 2004;351(27):2827-2831.
63. Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain. 1998;76(1-2):27-33.
64. Barkin RL, Iusco AM, Barkin SJ. Opioids used in primary care for the management of pain: a pharmacologic, pharmacotherapeutic, and pharmacodynamic overview. In: Boswell MV, Cole BE, eds. Weiner's Pain Management: A Practical Guide for Clinicians. 7th ed. New York, NY: CRC Press/Taylor & Francis Group; 2006:789-804.
65. Hucks D, Thompson PI, McLoughlin L, et al. Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronide. Br J Cancer. 1992;65(1):122-126.
66. Cann C, Curran J, Milner T, Ho B. Unwanted effects of morphine-6-glucoronide and morphine. Anaesthesia. 2002;57(12):1200-1203.
67. Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther. 2000;68(6):667-676.
68. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000;27(7):524-528.
69. Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci. 2001;69(4):409-420.
70. Wright AW, Nocente ML, Smith MT. Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation. Life Sci. 1998;63(5):401-411.
71. Klepstad P, Borchgrevink PC, Dale O, et al. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med. 2003;17:679-687.
72. Quigley C, Joel S, Patel N, Baksh A, Slevin M. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med. 2003;17(2):185-190.
73. Angst MS, Buhrer M, Lötsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology. 2000;92(5):1473-1476.
74. Hagen NA, Foley KM, Cerbone DJ, Portenoy RK, Inturrisi CE. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage. 1991;6(3):125-128.
75. Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther. 1993;54(2):158-167.
76. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed). 1986;292(6535): 1548-1549.
77. Halling J, Weihe P, Brosen K. CYP2D6 polymorphism in relation to tramadol metabolism: a study of Faroese patients. Ther Drug Monit. 2008; 30(3):271-275.
78. Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human μ-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(2):116-121.
79. Driessen B, Reimann W. Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol. 1992;105(1):147-151.
80. Driessen B, Reimann W, Giertz H. Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. Br J Pharmacol. 1993;108(3):806-811.
81. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461-479.
82. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes: role of CYP3A4. Drug Metab Dispos. 1996;24(9):932-939.
83. Inturrisi CE. Pharmacology of methadone and its isomers. Minerva Anestesiol. 2005;71(7-8):435-437.
84. Bush E, Miller C, Friedman I. A case of serotonin syndrome and mutism associated with methadone. J Palliat Med. 2006;9(6):1257-1259.
85. Ito S, Liao S. Myoclonus associated with high-dose parenteral methadone. J Palliat Med. 2008;11(6):838-841.
86. Sarhill N, Davis MP, Walsh D, Nouneh C. Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Care. 2001;18(1):51-53.
87. He YJ, Brockmöller J, Schmidt H, Roots I, Kirchheiner J. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? J Anal Toxicol. 2008;32(2):178-182.
88. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007 Aug;7(4):257-265. Epub 2006 Jul 4.
89. Cone EJ, Welch P, Paul BD, Mitchell JM. Forensic drug testing for opiates, III: Urinary excretion rates of morphine and codeine following codeine administration. J Anal Toxicol. 1991;15(4):161-166.
90. Solomon MD. A study of codeine metabolism. Clin Toxicol. 1974;7(3): 255-257.
91. Dutt MC, Lo DS, Ng DL, Woo SO. Gas chromatographic study of the urinary codeine-to-morphine ratios in controlled codeine consumption and in mass screening for opiate drugs. J Chromatogr. 1983;267(1):117-124.
92. Posey BL, Kimble SN. Simultaneous determination of codeine and morphine in urine and blood by HPLC. J Anal Toxicol. 1983;7(5):241-245.
93. George S, Braithwaite RA. A pilot study to determine the usefulness of the urinary excretion of methadone and its primary metabolite (EDDP) as potential markers of compliance in methadone detoxification programs. J Anal Toxicol. 1999;23(2):81-85.
94. Levine B, ed. Principles of Forensic Toxicology. 2nd ed. Washington, DC: AACC Press; 2003:385.
95. Caraco Y, Sheller J, Wood AJ. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther. 1999;290(1):413-422.
96. Ahdieh H. Regarding CYP450 2D6 poor metabolizers [letter]. Pain Pract. 2008;8(4):329.
97. Foster A. In response to Dr. Ahdieh [published online ahead of print May 26, 2008]. Pain Pract. doi10.1111/j.1533-2500.2008.00218-2.x.
98. Hasselström J, Eriksson S, Persson A, Rane A, Svensson JO, Säwe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29(3):289-297.
99. Crotty B, Watson KJ, Desmond PV, et al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol. 1989;36(5):501-506.
100. Haberer JP, Schoeffler P, Couderc E, Duvaldestin P. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth. 1982;54(12): 1267-1270.
101. Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 1981;30(3):353-362.
102. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278-285.
103. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31(2):155-163.
104. Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med. 1986;80(3):435-442.
105. Milne RW, Nation RL, Somogyi AA, Bochner F, Griggs WM. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol. 1992;34(1): 53-59.
106. Pauli-Magnus C, Hofmann U, Mikus G, Kuhlmann U, Mettang T. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1999;14(4):903-909.
107. Wolff J, Bigler D, Christensen CB, Rasmussen SN, Andersen HB, Tønnesen KH. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol. 1988;34(4):353-357.
108. Dubs A, Wiedemeier P, Caduff B. Morphine poisoning in chronic kidney failure: morphine-6-glucuronide as a pharmacologically active morphine metabolite [in German]. Dtsch Med Wochenschr. 1999;124(30):896-898.
109. Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure [letter]. J Pain Symptom Manage. 1995;10(3):184-186.
110. Furlan V, Hafi A, Dessalles MC, Bouchez J, Charpentier B, Taburet AM. Methadone is poorly removed by haemodialysis [letter]. Nephrol Dial Transplant. 1999;14(1):254-255.
111. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend. 1980;5(3):197-205.
112. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497-504.
113. Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy. 1997;17(4):746-752.
114. Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P. Morphine pharmacokinetics in renal failure. Anesthesiology. 1987;66(3):327-331.
115. Sear JW, Hand CW, Moore RA, McQuay HJ. Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. Br J Anaesth. 1989;62(1):28-32.
116. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother. 2007;21(2):5-16.